Akebia Therapeutics (NASDAQ:AKBA) Cut to Strong Sell at Wall Street Zen

Akebia Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Akebia Therapeutics to “strong sell”, while analyst views remain mixed: MarketBeat reports an average rating of “Hold” and an average price target of $3.50.
  • The stock opened at $0.45 and is near its 12-month low of $0.36; its 50-day and 200-day moving averages were $0.76 and $1.10, respectively.
  • Akebia met analysts’ quarterly EPS estimate at a loss of $0.04 per share, but revenue of $36.9 million came in below the $46.94 million forecast.
  • Five stocks we like better than Akebia Therapeutics.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Tuesday, Wall Street Zen reports.

Several other brokerages have also commented on AKBA. Westpark Capital started coverage on shares of Akebia Therapeutics in a research report on Tuesday, September 8th. They issued a "buy" rating and a $4.50 price objective on the stock. Piper Sandler reduced their target price on shares of Akebia Therapeutics to $2.00 and set an "overweight" rating for the company in a research report on Monday. BTIG Research restated a "buy" rating and set a $4.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, September 15th. Weiss Ratings cut shares of Akebia Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 2nd. Finally, Leerink Partners downgraded Akebia Therapeutics from an "outperform" rating to a "market perform" rating and set a $1.00 price objective on the stock. in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Akebia Therapeutics currently has an average rating of "Hold" and an average price target of $3.50.

View Our Latest Analysis on Akebia Therapeutics

Akebia Therapeutics Price Performance

Akebia Therapeutics stock opened at $0.45 on Tuesday. Akebia Therapeutics has a 12 month low of $0.36 and a 12 month high of $1.83. The company has a current ratio of 1.36, a quick ratio of 1.35 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average price of $0.76 and a two-hundred day moving average price of $1.10.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). The company had revenue of $36.90 million for the quarter, compared to analyst estimates of $46.94 million. Akebia Therapeutics had a negative net margin of 22.60% and a negative return on equity of 156.59%. On average, equities research analysts expect that Akebia Therapeutics will post -0.17 EPS for the current year.

Institutional Trading of Akebia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Akebia Therapeutics during the second quarter valued at approximately $22,784,000. Bank of America Corp DE increased its holdings in Akebia Therapeutics by 22.4% during the 1st quarter. Bank of America Corp DE now owns 2,763,362 shares of the biopharmaceutical company's stock worth $3,841,000 after acquiring an additional 505,951 shares during the period. Nantahala Capital Management LLC bought a new stake in Akebia Therapeutics during the 2nd quarter worth approximately $2,280,000. Hennion & Walsh Asset Management Inc. lifted its stake in Akebia Therapeutics by 32.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 839,729 shares of the biopharmaceutical company's stock worth $957,000 after purchasing an additional 206,476 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Akebia Therapeutics in the 2nd quarter worth approximately $706,000. 33.92% of the stock is currently owned by institutional investors.

Akebia Therapeutics Company Profile

(Get Free Report)

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company's work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).

See Also

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Akebia Therapeutics Right Now?

Before you consider Akebia Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.

While Akebia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines